VCAP/AMP/VECP(mLSG15) + KW-0761
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adult T-cell Leukemia-Lymphoma
Conditions
Adult T-cell Leukemia-Lymphoma
Trial Timeline
Jul 1, 2010 → Apr 1, 2012
NCT ID
NCT01173887About VCAP/AMP/VECP(mLSG15) + KW-0761
VCAP/AMP/VECP(mLSG15) + KW-0761 is a phase 2 stage product being developed by Kyowa Kirin for Adult T-cell Leukemia-Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01173887. Target conditions include Adult T-cell Leukemia-Lymphoma.
What happened to similar drugs?
9 of 20 similar drugs in Adult T-cell Leukemia-Lymphoma were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01173887 | Phase 2 | Completed |
Competing Products
20 competing products in Adult T-cell Leukemia-Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 + sotorasib | BridgeBio Pharma | Phase 1 | 18 |
| Daridorexant + Placebo | Idorsia | Phase 1 | 23 |
| SON-1010 (IL12-FHAB) | Sonnet BioTherapeutics | Phase 1 | 23 |
| Somatropin | Eli Lilly | Phase 3 | 40 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| Pegilodecakin | Eli Lilly | Phase 1 | 29 |
| eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab | eFFECTOR Therapeutics | Phase 1/2 | 29 |
| Lazertinib(G001) + Lazertinib(G002) | Yuhan | Phase 1 | 29 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 29 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 35 |
| Roxadustat | Astellas Pharma | Phase 1 | 29 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 29 |
| TRK-100STP | Astellas Pharma | Phase 1 | 29 |
| Ensitrelvir | Shionogi | Phase 1 | 29 |
| E6130 + Placebo | Eisai | Phase 1 | 29 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 29 |
| Eribulin Mesylate | Eisai | Phase 1 | 29 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 29 |
| Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride | Eisai | Phase 1 | 29 |